Market Insights
Articles
Latest
View All-
Boeing’s troubles just won’t go away
Just when it looked like Boeing (NYSE: BA) had finally turned around from its myriad of woes, the U.S. aerospace giant stepped in it again. Last week, the company said it would delay deliveries of some 737 Max planes, after finding a flaw on newly-built versions of its flagship narrow-body aircraft. The problem is scratched […]
-
In the asset management space, don’t sleep on LPL
When you hear about the wealth advisory business, your first thought is probably names like Goldman Sachs (NYSE: GS) and Morgan Stanley (NYSE: MS). One player that gets less attention is the country’s biggest independent broker-dealer, LPL Financial (NASDAQ: LPLA). You can think of it as a back office for financial advisors at independent wealth […]
-
Wyndham Hotels & Resorts sees boost from World Cup, leisure travelers
Known for its more economical hotels such as La Quinta, Days Inn, and Ramada, Wyndham Hotels & Resorts (NYSE: WH) is benefiting from the high demand in leisure travel. Travelers have been resilient and have continued to drive and fly to their favorite destinations despite some economic roadblocks. In 2025, the Transportation Security Administration screened […]
-
Dick’s looks supreme in world of sporting goods
The retail sporting goods industry has shrunk to one major national player: Dick’s Sporting Goods (NYSE: DKS). Dick’s and athletic-shoe retailer Foot Locker accounted for 25% of the U.S. retail sporting goods market in 2024, according to Euromonitor. Dick’s bought Foot Locker last year for $2.4 billion. Foot Locker has about 2,560 stores and the […]
-
Urban Outfitters is counting on subscription model to boost profit
The allure of receiving new clothing once a month is a deal that many shoppers do not want to pass up, benefiting companies such as Urban Outfitters (NASDAQ: URBN), which offer a subscription service. Keeping clothing for several years has lost some of its luster. Instead, consumers who like to keep up with fashion trends […]
-
Jazz Pharmaceuticals shifts focus to expand drug pipeline
Jazz Pharmaceuticals (NASDAQ: JAZZ) is leaning more toward generating growth from its group of oncology drugs to expand the company’s portfolio. Several drugs were approved recently, including two treatments in 2025 – Zepzelca to treat metastatic small cell lung cancer and Modeyso to treat a rare brain tumor. Diversifying its portfolio with acquisitions has […]
